title: TIMP-1 gene polymorphism: are genetics able to predict outcome of septic patients?
abstract: The multicenter study conducted by Lorente and coworkers - published in the previous issue of Critical Care - suggests that levels of tissue inhibitor of metalloproteinase (TIMP)-1 in association with the 372 T/C genetic polymorphism of TIMP-1 are promising markers to predict the clinical outcome of septic patients. TIMPs bind to active matrix metalloproteinases and, amongst other effects, inhibit their proteolytic activity of the extracellular matrix. Previous clinical studies showed increased plasma levels of TIMP-1 in nonsurvivors of sepsis, and showed associations between the 372 T/C genetic polymorphism of TIMP-1 and increased risk of developing certain diseases. In recent years, there has been great interest in understanding whether genetic determinants of the host response to systemic infections are associated with poor outcome. Furthermore, the pharmacogenomics of sepsis may allow us to target immune-modulating therapies. Measurement of TIMP-1 protein levels and TIMP-1 polymorphism 372 T/C in the intensive care setting could therefore be an attractive noninvasive tool to determine the outcome of septic patients, and might help to select patients potentially benefitting from a target-specific immune-modulatory therapy directed to matrix metalloproteinase/TIMP homeostasis.
authors.forename: Michael
authors.initials: M
authors.lastname: Behnes
authors.forename: Thomas
authors.initials: T
authors.lastname: Bertsch
authors.forename: Ursula
authors.initials: U
authors.lastname: Hoffmann
mesh_terms: D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics*; D018805:Sepsis / Q000097:blood* / Q000235:genetics*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood* / Q000235:genetics*
chemical_list: D005819:Genetic Markers; C560822:TIMP1 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1
references.citation: Crit Care. 2010;14(6):R237
references.pmid: 21190579
references.citation: Infect Immun. 2004 Jan;72(1):82-8
references.pmid: 14688084
references.citation: J Infect Dev Ctries. 2012 Jul 23;6(7):555-62
references.pmid: 22842942
references.citation: Pharmacol Res. 2011 Dec;64(6):590-4
references.pmid: 21742038
references.citation: Helicobacter. 2009 Dec;14(6):580-7
references.pmid: 19889076
references.citation: Crit Care. 2009;13(5):R158
references.pmid: 19799791
references.citation: Genet Test Mol Biomarkers. 2012 Oct;16(10):1172-8
references.pmid: 22971139
references.citation: Hum Immunol. 2012 Sep;73(9):950-3
references.pmid: 22820628
references.citation: Scand J Infect Dis. 2006;38(10):867-72
references.pmid: 17008230
references.citation: Clin Chim Acta. 2009 Nov;409(1-2):127-31
references.pmid: 19758569
references.citation: Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H919-30
references.pmid: 22904159
references.citation: Gene. 2012 Jun 15;501(2):213-8
references.pmid: 22537674
references.citation: Crit Care. 2013 May 25;17(3):R94
references.pmid: 23706069
references.citation: Cytokine. 2013 Feb;61(2):676-81
references.pmid: 23317877
references.citation: Mol Med. 2009 Jul-Aug;15(7-8):275-82
references.pmid: 19593412